In December 2023, Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") and InxMed (Nanjing) Co., Ltd. ("InxMed") entered into an effective licensing cooperation agreement. According to the agreement, Escugen granted InxMed a non-exclusive global license to use its ADC technology platform, EZWi-Fit®, for the development of ADC products targeting specific antigens identified by InxMed. InxMed will be responsible for the preclinical research, clinical development, and commercial sales of these ADC products worldwide and will pay Escugen royalties (including upfront payments and milestone payments) as well as a percentage of net sales for each licensed product.

In November 2023, a signing ceremony for the product development cooperation framework agreement between Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") and Foreseen Biotechnology (Beijing) Co., Ltd. ("Foreseen") was successfully held in Shanghai.